In a fit of boundless national optimism, Peugeot and Renault (and a few years later Volvo) teamed up to make a new V8 for good power and performance. But that's not what the world got. We welcomed in ...
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want to see a proven return on capital employed (ROCE) that is increasing, and secondly ...
An expiring FDA program designed to incentivize research in pediatric rare disease may see new life. The Pediatric Rare Disease Priority Review Voucher (RPD PRV) provides sponsors of granted new ...
Fortress Biotech (FBIO) and its majority-owned subsidiary, Cyprium Therapeutics announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority ...
Even in the era of the FDA's Commissioner's National Priority Voucher (CNPV) program, Jazz Pharmaceuticals is showing that traditional priority review vouchers (PRVs) can catch a pretty penny. In fact ...
Rocket Pharmaceuticals has signed an agreement to sell its rare paediatric disease priority review voucher (PRV) for $180m to advance its gene therapy pipeline. The PRV was awarded after the US Food ...
PRV RENAMED: What's in a name? Apparently something, at least in the view of the U.S. Air Force, which says it is changing the name of the Personnel Recovery Vehicle (PRV) program to Combat Search and ...
BOSTON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that it has entered into a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results